Peer-influenced content. Sources you trust. No registration required. This is HCN.
Eyewire+
“This acquisition immediately advances Biogen’s ongoing transformation… with two approved, best-in-class medicines that complement our existing portfolio.” — Christopher Viehbacher, President and CEO, Biogen
Ophthalmology April 7th 2026
Ophthalmology Advisor
According to the study, the “tilt and tumble technique” for cataract surgery is significantly faster than the traditional divide and conquer approach while demonstrating comparable safety, energy use, and postoperative outcomes.
Glaucoma Physician
“In discussions with ophthalmologists and optometrists, nearly all say they would choose SLT first if it were their own eye. However, when asked how often their patients receive SLT as initial therapy, most report rates around 10%.” – John Berdahl, MD, Vance Thompson Vision
Ophthalmology March 24th 2026
Conexiant
TECNIS PureSee IOL is the first and only US FDA‑approved extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity
Retina Today
Although surgical retina procedures may use similar techniques, the CPT code that accurately reflects the surgery performed is often best identified by the diagnosis that led to the surgery.
Ophthalmology November 25th 2025
Polaris has the potential to deliver more reliable outcomes for patients while giving surgeons the confidence that every case can be approached with greater consistency.